ANIP — ANI Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareAdventurousMid CapNeutral
- $695.26m
- $958.40m
- $316.39m
- 74
- 43
- 92
- 80
Annual cashflow statement for ANI Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 15.5 | 6.09 | -22.5 | -42.6 | -47.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 17.1 | 18.6 | 19 | 15.5 | 23.6 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 5.97 | -14.6 | -12.6 | -0.084 | -51.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 67.1 | 45.6 | 15.3 | 3.32 | -31.2 |
| Capital Expenditures | -5.74 | -6.63 | -6.13 | -2.56 | -8.88 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -21.6 | -20.9 | -62.2 | -103 | -6.86 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Change in Net Intangibles | |||||
| Cash from Investing Activities | -27.4 | -27.5 | -68.3 | -105 | -15.7 |
| Financing Cash Flow Items | -1.2 | 0 | — | -19.4 | 0 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -27.8 | 1.25 | -1.44 | 195 | -5.13 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.9 | 19.3 | -54.5 | 92.4 | -52.1 |